TY - JOUR T1 - Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors JO - Pulmonology T2 - AU - Serino,M. AU - Freitas,C. AU - Martins,M. AU - Ferreira,P. AU - Cardoso,C. AU - Veiga,F. AU - Santos,V. AU - Araújo,D. AU - Novais-Bastos,H. AU - Magalhães,A. AU - Queiroga,H. AU - Fernandes,G. AU - Hespanhol,V. SN - 25310437 M3 - 10.1016/j.pulmoe.2022.03.003 DO - 10.1016/j.pulmoe.2022.03.003 UR - https://journalpulmonology.org/en-predictors-immune-related-adverse-events-outcomes-avance-S2531043722000769 AB - ObjectiveTo identify predictors of immune-related adverse events (IRAEs) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Assess associations between outcomes and the development of IRAEs. MethodsRetrospective analysis of patients with NSCLC treated with ICIs between 2016 and 2020 in the Pulmonology Department of our hospital. Patients with and without IRAEs were compared. A logistic regression analysis was performed to determine predictors of IRAEs. Progression-free survival (PFS) and overall survival (OS) curves were calculated using the Kaplan-Meier method, and the long-rank test was used to assess survival differences between groups. Univariate and multivariate Cox proportional-hazards regression models were used to identify factors associated with PFS and OS. The value considered statistically significant was p≤0.05. ResultsA total of 184 patients (77.7% men, mean age 66.9±9.5 years) treated with ICIs were analyzed. During follow-up, 49 (26.6%) patients developed IRAEs and 149 (81.0%) died. According to the multivariate logistic regression analysis, treatment with statins (OR:3.15; p = 0.007), previous systemic corticosteroid therapy (OR:3.99; p = 0.001), disease controlled as response to ICI (OR:5.93; p < 0.001) and higher hemoglobin values (OR:1.28; p = 0.040) were independent predictors for the development of IRAEs. Patients who developed IRAEs had significantly longer medians of PFS (41.0 vs 9.0 weeks, p < 0.001) and OS (89.0 vs 28.0 weeks; p < 0.001). ConclusionsPatients treated with statins, pre-ICI systemic corticosteroids, higher baseline hemoglobin value and controlled disease as initial response to ICI had a higher risk of developing IRAEs. The development of IRAEs was associated with better outcomes. ER -